<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="confer">
<roleset id="confer.01" name="" wordnet="2">
<roles>
  <role n="0" descr="agent		// mechanism, process, entity(imply to condition or property in that entity) // 
"/>
  <role n="1" descr="given biological property	
"/>
  <role n="2" descr="entity receiving the biological property	         // gene product, celll, tissue, etc. //
"/>
</roles>
<example src="MEDLINE" no="1">
<text>
In addition to clear loss-of-function mutations conferred by nonsense or frameshift alterations in the coding sequence or by splice variants, genetic screening has revealed a large number of missense codons with less obvious functional consequences.

</text>
       <arg n="0">[by] nonsense or frameshift alterations in the coding sequence or by splice variants
</arg>
       <arg n="1">loss-of-function mutations
</arg>
       <arg n="2">-
</arg>
<fdg>
     1	In	in	cla:&gt;25	@ADVL %EH PREP
     2	addition	addition	pcomp:&gt;1	@&lt;P %NH N NOM SG
     3	to	to	pm:&gt;4	@INFMARK&gt; %AUX INFMARK&gt;
     4	clear	clear	cnt:&gt;25	@-FMAINV %VA V INF
     5	loss-of-function	loss-of-function	attr:&gt;6	@A&gt; %&gt;N &lt;?&gt; N NOM SG
     6	mutations	mutation	obj:&gt;4	@OBJ %NH N NOM PL
     7	conferred	confer	mod:&gt;6	@-FMAINV %VP EN
     8	by	by	ha:&gt;7	@ADVL %EH PREP
     9	nonsense	nonsense	cc:&gt;11	@A&gt; %&gt;N N NOM SG
     10	or	or	cc:&gt;11	@CC %CC CC
     11	frameshift	frameshift	attr:&gt;12	@A&gt; %&gt;N &lt;?&gt; N NOM SG
     12	alterations	alteration	pcomp:&gt;8	@&lt;P %NH N NOM PL
     13	in	in	mod:&gt;12	@&lt;NOM %N&lt; PREP
     14	the	the	det:&gt;16	@DN&gt; %&gt;N DET
     15	coding	coding	attr:&gt;16	@A&gt; %&gt;N A ABS
     16	sequence	sequence	pcomp:&gt;13	@&lt;P %NH N NOM SG
     17	or	or	cc:&gt;13	@CC %CC CC
     18	by	by	cc:&gt;13	@ADVL %EH PREP
     19	splice	splice	attr:&gt;20	@A&gt; %&gt;N N NOM SG
     20	variants	variant	pcomp:&gt;18	@&lt;P %NH N NOM PL
     21	,	,
     22	genetic	genetic	attr:&gt;23	@A&gt; %&gt;N A ABS
     23	screening	screening	subj:&gt;24	@SUBJ %NH N NOM SG
     24	has	have	v-ch:&gt;25	@+FAUXV %AUX V PRES SG3
     25	revealed	reveal	main:&gt;0	@-FMAINV %VA EN
     26	a	a	det:&gt;28	@DN&gt; %&gt;N DET SG
     27	large	large	attr:&gt;28	@A&gt; %&gt;N A ABS
     28	number	number	obj:&gt;25	@OBJ %NH N NOM
     29	of	of	mod:&gt;28	@&lt;NOM-OF %N&lt; PREP
     30	missense	missense	attr:&gt;31	@A&gt; %&gt;N &lt;?&gt; N NOM SG
     31	codons	codon	pcomp:&gt;29	@&lt;P %NH N NOM PL
     32	with	with		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
     33	less	little	ad:&gt;34	@AD-A&gt; %E&gt; ADV CMP
     34	obvious	obvious	attr:&gt;35	@A&gt; %&gt;N A ABS
     35	functional	functional	attr:&gt;36	@A&gt; %&gt;N A ABS
     36	consequences	consequence	pcomp:&gt;32	@&lt;P %NH N NOM PL
     37	.     .
</fdg>
</example>
<example src="MEDLINE" no="2">
<text>
In itself, the gene variant does not confer an increased risk of diabetes.

</text>
       <arg n="0">the gene variant
</arg>
       <arg n="1">an increased risk of diabetes
</arg>
       <arg n="2">-
</arg>
       <arg n="M-NEG">not
</arg>
<fdg>
     
     1	In	in	cla:&gt;9	@ADVL %EH PREP
     2	itself	it	pcomp:&gt;1	@&lt;P %NH &lt;Refl&gt; PRON SG3
     3	,	,
     4	the	the	det:&gt;6	@DN&gt; %&gt;N DET
     5	gene	gene	attr:&gt;6	@A&gt; %&gt;N N NOM SG
     6	variant	variant	subj:&gt;7	@SUBJ %NH N NOM SG
     7	does	do	v-ch:&gt;9	@+FAUXV %AUX V PRES SG3
     8	not	not	neg:&gt;7	@ADVL %EH NEG-PART
     9	confer	confer	main:&gt;0	@-FMAINV %VA V INF
     10	an	an	det:&gt;12	@DN&gt; %&gt;N DET SG
     11	increased	increased	attr:&gt;12	@A&gt; %&gt;N A ABS
     12	risk	risk	obj:&gt;9	@OBJ %NH N NOM SG
     13	of	of	mod:&gt;12	@&lt;NOM-OF %N&lt; PREP
     14	diabetes	diabetes	pcomp:&gt;13	@&lt;P %NH N NOM SG
     15	.     .
</fdg>
</example>
<example src="EMBO" no="1">
<text>
The data from the chimeras indicate that the difference is due to the absence of carboxyl sequences in Stat1, since the Stat5 phenotype of stability in the presence of MG132 can be conferred on Stat1 by simply replacing the C-terminus with that of Stat5.

</text>
       <arg n="0">[by] simply replacing the C-terminus with that of Stat5
</arg>
       <arg n="1">the Stat5 phenotype of stability in the presence of MG132
</arg>
       <arg n="2">Stat1
</arg>
       <arg n="M-MOD">can
</arg>
<fdg>
     
1	The	the	det:&gt;2	@DN&gt; %&gt;N DET
2	data	data	subj:&gt;6	@SUBJ %NH N NOM
3	from	from	mod:&gt;2	@&lt;NOM %N&lt; PREP
4	the	the	det:&gt;5	@DN&gt; %&gt;N DET
5	chimeras	chimera	pcomp:&gt;3	@&lt;P %NH N NOM PL
6	indicate	indicate		@+FMAINV %VA V PRES
7	that	that	pm:&gt;10	@CS %CS CS
8	the	the	det:&gt;9	@DN&gt; %&gt;N DET
9	difference	difference	subj:&gt;10	@SUBJ %NH N NOM SG
10	is	be	obj:&gt;6	@+FMAINV %VA V PRES SG3
11	due to	due to	ha:&gt;10	@ADVL %EH PREP
12	the	the	det:&gt;13	@DN&gt; %&gt;N DET
13	absence	absence	pcomp:&gt;11	@&lt;P %NH N NOM SG
14	of	of	mod:&gt;13	@&lt;NOM-OF %N&lt; PREP
15	carboxyl	carboxyl	pcomp:&gt;14	@&lt;P %NH &lt;?&gt; N NOM SG
16	sequences	sequence		@+FMAINV %VA V PRES SG3
17	in	in	loc:&gt;16	@ADVL %EH PREP
18	Statl	statl	pcomp:&gt;17	@&lt;P %NH &lt;?&gt; N NOM SG
19	,	,
20	since	since	pm:&gt;33	@CS %CS CS
21	the	the	det:&gt;23	@DN&gt; %&gt;N DET
22	Stat5	stat5	attr:&gt;23	@A&gt; %&gt;N N NOM SG
23	phenotype	phenotype	subj:&gt;31	@SUBJ %NH N NOM SG
24	of	of	mod:&gt;23	@&lt;NOM-OF %N&lt; PREP
25	stability	stability	pcomp:&gt;24	@&lt;P %NH N NOM SG
26	in	in	mod:&gt;25	@&lt;NOM %N&lt; PREP
27	the	the	det:&gt;28	@DN&gt; %&gt;N DET
28	presence	presence	pcomp:&gt;26	@&lt;P %NH N NOM SG
29	of	of	mod:&gt;28	@&lt;NOM-OF %N&lt; PREP
30	MG132	mg132	pcomp:&gt;29	@&lt;P %NH N NOM SG
31	can	can	v-ch:&gt;32	@+FAUXV %AUX V AUXMOD
32	be	be	v-ch:&gt;33	@-FAUXV %AUX V INF
33	conferred	confer	cnt:&gt;16	@-FMAINV %VP EN
34	on	on	loc:&gt;33	@ADVL %EH PREP
35	Statl	statl	pcomp:&gt;34	@&lt;P %NH &lt;?&gt; N NOM SG
36	by	by		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
37	simply	simply		@ADVL %EH ADV	@AD-A&gt; %E&gt; ADV
38	replacing	replace	pcomp:&gt;36	@&lt;P-FMAINV %VA ING
39	the	the	det:&gt;40	@DN&gt; %&gt;N DET
40	C-terminus	c-terminus	obj:&gt;38	@OBJ %NH N NOM SG
41	with	with	phr:&gt;38	@ADVL %EH PREP
42	that	that	pcomp:&gt;41	@&lt;P %NH PRON DEM SG
43	of	of	mod:&gt;42	@&lt;NOM-OF %N&lt; PREP
44	Stat5	stat5	pcomp:&gt;43	@&lt;P %NH N NOM SG
45	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
Human 06-alkylguaning-DNA alkyltransferase (AGT), which directly reverses endogenous alkylation at the 06-position of guanine, confers resistance to alkylation chemotherapies and is therefore an active anticancer drug target.

</text>
       <arg n="0">Human 06-alkylguaning-DNA alkyltransferase 
</arg>
       <arg n="1">resistance 
</arg>
       <arg n="2">[to] alkylation chemotherapies
</arg>
<fdg>
1	Human	human	attr:&gt;2	@A&gt; %&gt;N A ABS
2	O6-alkylguanine-DNA	o6-alkylguanine-dna	attr:&gt;3	@A&gt; %&gt;N &lt;?&gt; N NOM SG
3	alkyltransferase	alkyltransferase		@NH %NH &lt;?&gt; N NOM SG	@SUBJ %NH &lt;?&gt; N NOM SG	@PCOMPL-S %NH &lt;?&gt; N NOM SG	@A&gt; %&gt;N &lt;?&gt; N NOM SG
4	(	(
5	AGT	agt		@NH %NH ABBR NOM SG
6	)	)
7	,	,
8	which	which	subj:&gt;10	@SUBJ %NH &lt;Rel&gt; PRON WH NOM
9	directly	directly	man:&gt;10	@ADVL %EH ADV
10	reverses	reverse	mod:&gt;5	@+FMAINV %VA V PRES SG3
11	endogenous	endogenous	attr:&gt;12	@A&gt; %&gt;N A ABS
12	alkylation	alkylation	obj:&gt;10	@OBJ %NH N NOM SG
13	at	at	loc:&gt;10	@ADVL %EH PREP
14	the	the	det:&gt;15	@DN&gt; %&gt;N DET
15	O6-position	o6-position	pcomp:&gt;13	@&lt;P %NH &lt;?&gt; N NOM SG
16	of	of	mod:&gt;15	@&lt;NOM-OF %N&lt; PREP
17	guanine	guanine	pcomp:&gt;16	@&lt;P %NH N NOM SG
18	,	,
19	confers	confer		@+FMAINV %VA V PRES SG3
20	resistance	resistance	obj:&gt;19	@OBJ %NH N NOM SG
21	to	to	mod:&gt;20	@&lt;NOM %N&lt; PREP
22	alkylation	alkylation	attr:&gt;23	@A&gt; %&gt;N N NOM SG
23	chemotherapies	chemotherapy	pcomp:&gt;21	@&lt;P %NH N NOM PL
24	and	and	cc:&gt;19	@CC %CC CC
25	is	be	cc:&gt;19	@+FMAINV %VA V PRES SG3
26	therefore	therefore	meta:&gt;25	@ADVL %EH ADV
27	an	an	det:&gt;31	@DN&gt; %&gt;N DET SG
28	active	active	attr:&gt;29	@A&gt; %&gt;N A ABS
29	anticancer	anticancer	attr:&gt;30	@A&gt; %&gt;N A ABS
30	drug	drug	attr:&gt;31	@A&gt; %&gt;N N NOM SG
31	target	target	comp:&gt;25	@PCOMPL-S %NH N NOM SG
32	.     .
</fdg>
</example>
<example src="EMBO" no="3">
<text>
Increased AGT levels parallel acquired alkylation resistance in human tumors (Brent et al., 1985; Mattern et al., 1998), and transfection of AGT confers resistance to alkylation-sensitive cells (Kaina et al., 1991), demonstrating the role of AGT  in therapeutic resistance.

</text>
       <arg n="0">transfection of AGT
</arg>
       <arg n="1">resistance
</arg>
       <arg n="2">[to] alkylation-sensitive cells
</arg>
<fdg>
1	Increased	increase		@-FMAINV %VP EN
2	AGT	agt	obj:&gt;1	@OBJ %NH ABBR NOM SG
3	levels	level	subj:&gt;4	@SUBJ %NH N NOM PL
4	parallel	parallel	main:&gt;0	@+FMAINV %VA V PRES
5	acquired	acquired	attr:&gt;6	@A&gt; %&gt;N A ABS
6	alkylation	alkylation	attr:&gt;7	@A&gt; %&gt;N N NOM SG
7	resistance	resistance	obj:&gt;4	@OBJ %NH N NOM SG
8	in	in	ha:&gt;4	@ADVL %EH PREP
9	human	human	attr:&gt;10	@A&gt; %&gt;N A ABS
10	tumors	tumor	pcomp:&gt;8	@&lt;P %NH N NOM PL
11	(	(
12	Brent	brent	main:&gt;11	@APP %NH N NOM SG
13	et	et	cc:&gt;12	@CC %CC CC
14	al.	al.	cc:&gt;12	@APP %NH ABBR NOM SG
15	,	,
16	1985	1985		@NH %NH NUM CARD	@&lt;P %NH NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
17	;	;
18	Mattern	mattern	main:&gt;17	@NH %NH N NOM SG
19	et	et	cc:&gt;18	@CC %CC CC
20	al.	al.	cc:&gt;18	@NH %NH ABBR NOM SG
21	,	,
22	1998	1998	cc:&gt;20	@NH %NH NUM CARD
23	)	)
24	,	,
25	and	and	cc:&gt;4	@CC %CC CC
26	transfection	transfection	subj:&gt;29	@SUBJ %NH &lt;?&gt; N NOM SG
27	of	of	mod:&gt;26	@&lt;NOM-OF %N&lt; PREP
28	AGT	agt	pcomp:&gt;27	@&lt;P %NH ABBR NOM SG
29	confers	confer	cc:&gt;4	@+FMAINV %VA V PRES SG3
30	resistance	resistance	obj:&gt;29	@OBJ %NH N NOM SG
31	to	to	mod:&gt;30	@&lt;NOM %N&lt; PREP
32	alkylation-sensitive	alkylation-sensitive	attr:&gt;33	@A&gt; %&gt;N A ABS
33	cells	cell	pcomp:&gt;31	@&lt;P %NH N NOM PL
34	(	(
35	Kaina	kaina	main:&gt;34	@APP %NH &lt;?&gt; N NOM SG
36	et	et		@CC %CC CC
37	al.	al.		@SUBJ %NH ABBR NOM SG	@OBJ %NH ABBR NOM SG	@APP %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@&lt;P %NH ABBR NOM SG	@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG
38	,	,
39	1991	1991		@NH %NH NUM CARD	@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
40	)	)
41	,	,
42	demonstrating	demonstrate	ha:&gt;29	@-FMAINV %VA ING
43	the	the	det:&gt;44	@DN&gt; %&gt;N DET
44	role	role	obj:&gt;42	@OBJ %NH N NOM SG
45	of	of	mod:&gt;44	@&lt;NOM-OF %N&lt; PREP
46	AGT	agt	pcomp:&gt;45	@&lt;P %NH ABBR NOM SG
47	in	in	mod:&gt;46	@&lt;NOM %N&lt; PREP
48	therapeutic	therapeutic	attr:&gt;49	@A&gt; %&gt;N A ABS
49	resistance	resistance	pcomp:&gt;47	@&lt;P %NH N NOM SG
50	.     .
</fdg>
</example>
<example src="EMBO" no="4">
<text>
Likewise, the introduced charge of Gly160His and Gly160Arg mutants would repel the benzyl group (Figure 3B), explaining the 06-BG resistance conferred by these mutations (Xu-Welliver et al., 1999a).

</text>
       <arg n="0">these mutations
</arg>
       <arg n="1">06-BG resistance
</arg>
       <arg n="2">-
</arg>
<fdg>
1	Likewise	likewise	meta:&gt;12	@ADVL %EH ADV
2	,	,
3	the	the	det:&gt;5	@DN&gt; %&gt;N DET
4	introduced	introduced	attr:&gt;5	@A&gt; %&gt;N A ABS
5	charge	charge	subj:&gt;11	@SUBJ %NH N NOM SG
6	of	of	mod:&gt;5	@&lt;NOM-OF %N&lt; PREP
7	Gly160His	gly160hi	pcomp:&gt;6	@&lt;P %NH &lt;?&gt; N NOM PL
8	and	and	cc:&gt;7	@CC %CC CC
9	Gly160Arg	gly160arg	attr:&gt;10	@A&gt; %&gt;N &lt;?&gt; N NOM SG
10	mutants	mutant	cc:&gt;7	@&lt;P %NH N NOM PL
11	would	would	v-ch:&gt;12	@+FAUXV %AUX V AUXMOD
12	repel	repel	main:&gt;0	@-FMAINV %VA V INF
13	the	the	det:&gt;15	@DN&gt; %&gt;N DET
14	benzyl	benzyl	attr:&gt;15	@A&gt; %&gt;N &lt;?&gt; N NOM SG
15	group	group	obj:&gt;12	@OBJ %NH N NOM
16	(	(
17	Figure	figure		@A&gt; %&gt;N N NOM SG
18	3B	3b	qua:&gt;12	@ADVL %EH NUM CARD
19	)	)
20	,	,
21	explaining	explain	man:&gt;12	@-FMAINV %VA ING
22	the	the	det:&gt;24	@DN&gt; %&gt;N DET
23	O6-BG	o6-bg	attr:&gt;24	@A&gt; %&gt;N &lt;?&gt; N NOM SG
24	resistance	resistance	obj:&gt;21	@OBJ %NH N NOM SG
25	conferred	confer	mod:&gt;24	@-FMAINV %VP EN
26	by	by	ha:&gt;25	@ADVL %EH PREP
27	these	this	det:&gt;28	@DN&gt; %&gt;N DET DEM PL
28	mutations	mutation	pcomp:&gt;26	@&lt;P %NH N NOM PL
29	(	(
30	Xu-Welliver	xu-welliver	main:&gt;29	@APP %NH &lt;?&gt; N NOM SG
31	et	et		@CC %CC CC
32	al.	al.		@SUBJ %NH ABBR NOM SG	@OBJ %NH ABBR NOM SG	@APP %NH ABBR NOM SG	@A&gt; %&gt;N ABBR NOM SG	@&lt;P %NH ABBR NOM SG	@NH %NH ABBR NOM SG	@&lt;NOM %N&lt; ABBR NOM SG
33	,	,
34	1999a	1999a		@NH %NH NUM CARD	@SUBJ %NH NUM CARD	@OBJ %NH NUM CARD	@&lt;P %NH NUM CARD	@A&gt; %&gt;N NUM CARD	@&lt;NOM %N&lt; NUM CARD	@ADVL %EH NUM CARD
35	)	)
36	.     .
</fdg>
</example>
<example src="EMBO" no="5">
<text>
Besides these side chain interactions with the 06-alkyl group, structure-based analysis of mutational data suggests that substitutions at Gly156 and Lys165 confer resistance to 06-BG through backbone distortions.

</text>
       <arg n="0">substitutions at Gly156 and Lys165
</arg>
       <arg n="1">resistance
</arg>
       <arg n="2">[to] 06-BG
</arg>
<fdg>
1	Besides	besides	cla:&gt;16	@ADVL %EH PREP
2	these	this	det:&gt;5	@DN&gt; %&gt;N DET DEM PL
3	side	side	attr:&gt;4	@A&gt; %&gt;N N NOM SG
4	chain	chain	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	interactions	interaction	pcomp:&gt;1	@&lt;P %NH N NOM PL
6	with	with	mod:&gt;5	@&lt;NOM %N&lt; PREP
7	the	the	det:&gt;9	@DN&gt; %&gt;N DET
8	O6-alkyl	o6-alkyl	attr:&gt;9	@A&gt; %&gt;N &lt;?&gt; N NOM SG
9	group	group	pcomp:&gt;6	@&lt;P %NH N NOM
10	,	,
11	structure-based	structure-based	attr:&gt;12	@A&gt; %&gt;N A ABS
12	analysis	analysis	subj:&gt;16	@SUBJ %NH N NOM SG
13	of	of	mod:&gt;12	@&lt;NOM-OF %N&lt; PREP
14	mutational	mutational	attr:&gt;15	@A&gt; %&gt;N A ABS
15	data	data	pcomp:&gt;13	@&lt;P %NH N NOM
16	suggests	suggest	main:&gt;0	@+FMAINV %VA V PRES SG3
17	that	that	pm:&gt;23	@CS %CS CS
18	substitutions	substitution	subj:&gt;23	@SUBJ %NH N NOM PL
19	at	at	mod:&gt;18	@&lt;NOM %N&lt; PREP
20	Gly156	gly156	pcomp:&gt;19	@&lt;P %NH N NOM SG
21	and	and	cc:&gt;20	@CC %CC CC
22	Lys165	lys165	cc:&gt;20	@&lt;P %NH N NOM SG
23	confer	confer	obj:&gt;16	@+FMAINV %VA V PRES	@+FMAINV %VA V SUBJUNCTIVE
24	resistance	resistance	obj:&gt;23	@OBJ %NH N NOM SG
25	to	to	mod:&gt;24	@&lt;NOM %N&lt; PREP
26	O6-BG	o6-bg	pcomp:&gt;25	@&lt;P %NH &lt;?&gt; N NOM SG
27	through	through	mod:&gt;26	@&lt;NOM %N&lt; PREP
28	backbone	backbone	attr:&gt;29	@A&gt; %&gt;N N NOM SG
29	distortions	distortion	pcomp:&gt;27	@&lt;P %NH N NOM PL
30	.     .
</fdg>
</example>
<example src="EMBO" no="6">
<text>
The portion of the STATs conferring specificity for either a MAPK or a MAPK substrate kinase (MAPKAP) has not been determined.

</text>
       <arg n="0">The portion of the STATs
</arg>
       <arg n="1">specificity
</arg>
       <arg n="2">[for] either a MAPK or a MAPK substrate kinase (MAPKAP)
</arg>
<fdg>
1	The	the	det:&gt;2	@DN&gt; %&gt;N DET
2	portion	portion		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG
3	of	of	mod:&gt;2	@&lt;NOM-OF %N&lt; PREP
4	the	the		@DN&gt; %&gt;N DET
5	STATs	stats		@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
6	conferring	conferring		@A&gt; %&gt;N A ABS	@&lt;P-FMAINV %VA ING	@-FMAINV %VA ING
7	specificity	specificity		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@&lt;P %NH N NOM SG
8	for	for		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
9	either	either		@ADVL %EH ADV
10	a	a	det:&gt;11	@DN&gt; %&gt;N DET SG
11	MAPK	mapk		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@&lt;P %NH N NOM SG
12	or	or		@CC %CC CC
13	a	a	det:&gt;16	@DN&gt; %&gt;N DET SG
14	MAPK	mapk	attr:&gt;15	@A&gt; %&gt;N N NOM SG
15	substrate	substrate	attr:&gt;16	@A&gt; %&gt;N N NOM SG
16	kinase	kinase	subj:&gt;20	@SUBJ %NH N NOM SG
17	(	(
18	MAPKAP	mapkap	mod:&gt;16	@NH %NH N NOM SG
19	)	)
20	has	have	v-ch:&gt;22	@+FAUXV %AUX V PRES SG3
21	not	not	neg:&gt;20	@ADVL %EH NEG-PART
22	been	be	v-ch:&gt;23	@-FAUXV %AUX EN
23	determined	determine		@-FMAINV %VP EN
24	.     .
</fdg>
</example>
</roleset>
</predicate>
</frameset>
